Epilepsy-Pipeline Review, H1 2017

Epilepsy-Pipeline Review, H1 2017


  • Products Id :- GMDHC9057IDB
  • |
  • Pages: 382
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Epilepsy-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy-Pipeline Review, H1 2017, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape.

Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, and anxiety, loss of consciousness and contraction, or jerking, of body muscles. Main causes of epilepsy include low oxygen during birth, head injuries that occur during birth or from accidents during youth or adulthood, brain tumors, genetic conditions that result in brain injury, such as tuberous sclerosis, infections such as meningitis or encephalitis, and stroke or any other type of damage to the brain.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epilepsy-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Epilepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epilepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 11, 15, 17, 2, 71, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 20 and 2 molecules, respectively.

Epilepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Epilepsy (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Epilepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Epilepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Epilepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Epilepsy (Central Nervous System)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Epilepsy (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Epilepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

Introduction 6

Epilepsy-Overview 7

Epilepsy-Therapeutics Development 8

Epilepsy-Therapeutics Assessment 29

Epilepsy-Companies Involved in Therapeutics Development 43

Epilepsy-Drug Profiles 78

Epilepsy-Dormant Projects 348

Epilepsy-Discontinued Products 355

Epilepsy-Product Development Milestones 357

Appendix 365

List of Figures

Number of Products under Development for Epilepsy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Epilepsy, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Epilepsy-Pipeline by Adamas Pharmaceuticals Inc, H1 2017

Epilepsy-Pipeline by Advicenne SA, H1 2017

Epilepsy-Pipeline by Aeolus Pharmaceuticals Inc, H1 2017

Epilepsy-Pipeline by Aequus Pharmaceuticals Inc, H1 2017

Epilepsy-Pipeline by Alexza Pharmaceuticals Inc, H1 2017

Epilepsy-Pipeline by Anavex Life Sciences Corp, H1 2017

Epilepsy-Pipeline by Asklepios BioPharmaceutical Inc, H1 2017

Epilepsy-Pipeline by Astellas Pharma Inc, H1 2017

Epilepsy-Pipeline by Bial-Portela & Ca SA, H1 2017

Epilepsy-Pipeline by BioCrea GmbH, H1 2017

Epilepsy-Pipeline by BioHealthonomics Inc, H1 2017

Epilepsy-Pipeline by Bionomics Ltd, H1 2017

Epilepsy-Pipeline by Biovista Inc, H1 2017

Epilepsy-Pipeline by Biscayne Pharmaceuticals Inc, H1 2017

Epilepsy-Pipeline by Catalyst Pharmaceuticals Inc, H1 2017

Epilepsy-Pipeline by Cerecor Inc, H1 2017

Epilepsy-Pipeline by D-Pharm Ltd, H1 2017

Epilepsy-Pipeline by Eisai Co Ltd, H1 2017

Epilepsy-Pipeline by Glialogix Inc, H1 2017

Epilepsy-Pipeline by Grifols SA, H1 2017

Epilepsy-Pipeline by GW Pharmaceuticals Plc, H1 2017

Epilepsy-Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017

Epilepsy-Pipeline by INSYS Therapeutics Inc, H1 2017

Epilepsy-Pipeline by INVENT Pharmaceuticals Inc, H1 2017

Epilepsy-Pipeline by Iproteos SL, H1 2017

Epilepsy-Pipeline by Johnson & Johnson, H1 2017

Epilepsy-Pipeline by Knopp Biosciences LLC, H1 2017

Epilepsy-Pipeline by Lead Discovery Center GmbH, H1 2017

Epilepsy-Pipeline by Lipicard Technologies Ltd, H1 2017

Epilepsy-Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017

Epilepsy-Pipeline by Marathon Pharmaceuticals LLC, H1 2017

Epilepsy-Pipeline by Marinus Pharmaceuticals Inc, H1 2017

Epilepsy-Pipeline by Medicure Inc, H1 2017

Epilepsy-Pipeline by Mitochon Pharmaceuticals Inc, H1 2017

Epilepsy-Pipeline by Monosol Rx LLC, H1 2017

Epilepsy-Pipeline by Neurelis Inc, H1 2017

Epilepsy-Pipeline by Neurocrine Biosciences Inc, H1 2017

Epilepsy-Pipeline by NeuroCycle Therapeutics GmbH, H1 2017

Epilepsy-Pipeline by Neuron Biopharma SA, H1 2017

Epilepsy-Pipeline by Novartis AG, H1 2017

Epilepsy-Pipeline by OPKO Health Inc, H1 2017

Epilepsy-Pipeline by Ovid Therapeutics Inc, H1 2017

Epilepsy-Pipeline by Pfizer Inc, H1 2017

Epilepsy-Pipeline by PharmatrophiX Inc, H1 2017

Epilepsy-Pipeline by Promius Pharma LLC, H1 2017

Epilepsy-Pipeline by Proximagen Ltd, H1 2017

Epilepsy-Pipeline by PTC Therapeutics Inc, H1 2017

Epilepsy-Pipeline by Retrophin Inc, H1 2017

Epilepsy-Pipeline by Sage Therapeutics Inc, H1 2017

Epilepsy-Pipeline by Saniona AB, H1 2017

Epilepsy-Pipeline by SciFluor Life Sciences LLC, H1 2017

Epilepsy-Pipeline by Serina Therapeutics Inc, H1 2017

Epilepsy-Pipeline by Shire Plc, H1 2017

Epilepsy-Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017

Epilepsy-Pipeline by Suda Ltd, H1 2017

Epilepsy-Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Epilepsy-Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Epilepsy-Pipeline by Trillium Therapeutics Inc, H1 2017

Epilepsy-Pipeline by Turing Pharmaceuticals AG, H1 2017

Epilepsy-Pipeline by UCB SA, H1 2017

Epilepsy-Pipeline by Ultragenyx Pharmaceutical Inc, H1 2017

Epilepsy-Pipeline by Upsher-Smith Laboratories Inc, H1 2017

Epilepsy-Pipeline by VistaGen Therapeutics Inc, H1 2017

Epilepsy-Pipeline by Vitality Biopharma Inc, H1 2017

Epilepsy-Pipeline by Xenon Pharmaceuticals Inc, H1 2017

Epilepsy-Pipeline by XERIS Pharmaceuticals Inc, H1 2017

Epilepsy-Pipeline by Zogenix Inc, H1 2017

Epilepsy-Pipeline by Zynerba Pharmaceuticals Inc, H1 2017

Epilepsy-Dormant Projects, H1 2017

Epilepsy-Dormant Projects, H1 2017 (Contd..1), H1 2017

Epilepsy-Dormant Projects, H1 2017 (Contd..2), H1 2017

Epilepsy-Dormant Projects, H1 2017 (Contd..3), H1 2017

Epilepsy-Dormant Projects, H1 2017 (Contd..4), H1 2017

Epilepsy-Dormant Projects, H1 2017 (Contd..5), H1 2017

Epilepsy-Discontinued Products, H1 2017

Epilepsy-Discontinued Products, H1 2017 (Contd..1), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Adamas Pharmaceuticals Inc, Advicenne SA, Aeolus Pharmaceuticals Inc, Aequus Pharmaceuticals Inc, Alexza Pharmaceuticals Inc, Anavex Life Sciences Corp, Asklepios BioPharmaceutical Inc, Astellas Pharma Inc, Bial-Portela & Ca SA, BioCrea GmbH, BioHealthonomics Inc, Bionomics Ltd, Biovista Inc, Biscayne Pharmaceuticals Inc, Catalyst Pharmaceuticals Inc, Cerecor Inc, D-Pharm Ltd, Eisai Co Ltd, Glialogix Inc, Grifols SA, GW Pharmaceuticals Plc, Hyundai Pharmaceutical Co Ltd, INSYS Therapeutics Inc, INVENT Pharmaceuticals Inc, Iproteos SL, Johnson & Johnson, Knopp Biosciences LLC, Lead Discovery Center GmbH, Lipicard Technologies Ltd, Lotus Pharmaceutical Co Ltd, Marathon Pharmaceuticals LLC, Marinus Pharmaceuticals Inc, Medicure Inc, Mitochon Pharmaceuticals Inc, Monosol Rx LLC, Neurelis Inc, Neurocrine Biosciences Inc, NeuroCycle Therapeutics GmbH, Neuron Biopharma SA, Novartis AG, OPKO Health Inc, Ovid Therapeutics Inc, Pfizer Inc, PharmatrophiX Inc, Promius Pharma LLC, Proximagen Ltd, PTC Therapeutics Inc, Retrophin Inc, Sage Therapeutics Inc, Saniona AB, SciFluor Life Sciences LLC, Serina Therapeutics Inc, Shire Plc, SK Biopharmaceuticals Co Ltd, Suda Ltd, Sumitomo Dainippon Pharma Co Ltd, Takeda Pharmaceutical Company Ltd, Trillium Therapeutics Inc, Turing Pharmaceuticals AG, UCB SA, Ultragenyx Pharmaceutical Inc, Upsher-Smith Laboratories Inc, VistaGen Therapeutics Inc, Vitality Biopharma Inc, Xenon Pharmaceuticals Inc, XERIS Pharmaceuticals Inc, Zogenix Inc, Zynerba Pharmaceuticals Inc

Epilepsy Therapeutic Products under Development, Key Players in Epilepsy Therapeutics, Epilepsy Pipeline Overview, Epilepsy Pipeline, Epilepsy Pipeline Assessment

select a license
Single User License
USD 2000 INR 144740
Site License
USD 4000 INR 289480
Corporate User License
USD 6000 INR 434220

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com